细胞外囊泡作为创伤性脑损伤生物标志物:动物与临床研究的系统综述
该系统综述按PRISMA指南检索4个数据库至2024年12月31日,纳入18项动物研究和19项人类研究,评估EV作为TBI生物标志物的作用。动物研究中最常检出miRNA,人类研究中最常检出蛋白质,以GFAP、UCH-L1、Tau及miRNA-124-3p反复出现;EV最常从血浆获取,动物研究其次为脑组织裂解液,人类研究其次为脑脊液或唾液;分离多采用超速离心或聚合物沉淀法,表征多用蛋白质印迹和电子显微镜。少数研究报告了诊断准确性,最高诊断性能见于神经来源EV的miRNA组合;仅有限研究探索预后价值,少数使用GOS-E等量表或评估长期神经认知并发症。作者认为EV生物标志物有潜力,但需标准化分离与表征方案,并需更多研究评估其预后价值。
要点
- 该系统综述纳入18项动物研究和19项人类研究,评估EV作为TBI生物标志物,动物研究以miRNA最常见,人类研究以蛋白质最常见。
- EV中最常检出的蛋白质为GFAP、UCH-L1和Tau,miRNA-124-3p也被反复发现。
- EV最常从血浆获取,动物研究其次为脑组织裂解液,人类研究其次为脑脊液或唾液。
- 少数研究报告诊断准确性,最高诊断性能见于神经来源EV的miRNA组合。
- 仅有限研究探讨预后价值,少数使用GOS-E或评估长期神经认知并发症。
适用人群与场景
- 纳入成人或急性TBI实验模型的研究,损伤机制和严重程度不限,且研究伤后第一周内的生物标志物。
- 纳入动物研究以及人类队列、病例对照和病例系列研究;排除既往综述、会议摘要和非同行评议作品。
研究设计与关键结果
- 该系统综述按PRISMA指南检索4个电子数据库,从建库至2024年12月31日,最终纳入18项动物研究和19项人类研究。
- 动物研究中最常检出的EV生物标志物为miRNA,人类研究中最常检出的为蛋白质,以GFAP、UCH-L1和Tau最常见,miRNA-124-3p也被反复发现。
- EV最常从血浆获取,动物研究其次为脑组织裂解液,人类研究其次为脑脊液或唾液。
- 多数研究采用超速离心或聚合物沉淀法分离EV,采用蛋白质印迹和电子显微镜进行表征。
- 少数研究报告了所研究生物标志物的诊断准确性,最高诊断性能见于神经来源EV的miRNA组合。
- 仅有限研究探讨EV生物标志物的预后价值,少数使用GOS-E等量表或评估长期神经认知并发症。
证据类型、等级与局限
- 证据类型:系统综述,纳入动物研究和人类队列、病例对照及病例系列研究。
- 研究间实验设计、外泌体分离方法和研究人群存在显著异质性。
- 作者指出需要标准化的EV分离与表征方案以保证研究间的一致性。
- 作者指出需要更多研究评估EV生物标志物的预后价值,尤其是神经功能结局,未来研究应纳入性能指标以评估临床相关性。
对床旁实践的改变
- 该系统综述提示EV来源的GFAP、UCH-L1、Tau及miRNA-124-3p在TBI中被反复检出,但诊断准确性和预后价值证据有限,标准化方案尚待建立。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Traumatic brain injury (TBI) is one of the leading causes of disability worldwide. Clinical or imaging scales are currently used to stratify severity, but they show a limited correlation with clinical prognosis, which has raised interest in biomarkers. Extracellular vesicles (EV)-based biomarkers may be superior to soluble biomarkers because of their stability, resistance to degradation and unique signature according to tissue of origin. Identification of EV-associated TBI biomarkers remains challenging due to the significant heterogeneity in experimental design, exosome isolation methods and study populations. This systematic review aims to analyze the role of EVs as biomarkers in TBI across both animal and clinical models, with particular focus on their association with prognosis. METHODS: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Four electronic databases were searched from inception to December 31st, 2024, using the terms “traumatic brain injury”, “extracellular vesicles” and “biomarkers”. Animal studies and human cohort, case control, and case series studies were included; previous reviews, congress abstracts, and non-peer-reviewed works were excluded. Studies conducted on adult individuals or in experimental models of acute TBI, regardless of the mechanism and severity, and which studied biomarkers within the first week of injury, were included. The primary outcome was the EV-based biomarker identified by each study and its diagnostic accuracy when provided. Secondary outcomes were sample type for EV isolation, origin of EVs and methods for isolation and characterization. RESULTS: A total of 18 animal and 19 human studies were included. miRNAs were the most frequently identified biomarker in animal studies, while proteins were most common in human studies. The most commonly identified proteins in EVs were GFAP, UCH-L1, and Tau, with miRNA-124-3p also being repeatedly found. EVs were most frequently obtained from plasma, followed by brain tissue lysates in animals and cerebrospinal fluid or saliva in humans. Most studies used ultracentrifugation or polymer-based precipitation for EV isolation, with western blotting and electron microscopy for characterization. Few studies provided a measure of accuracy for the studied biomarkers; the highest diagnostic performance has been achieved with neural EV-based miRNA panels. While several studies explored diagnostic applications, only a limited number investigated prognostic utility, with few using scales such as GOS-E or evaluating long-term neurocognitive complications. CONCLUSIONS: This review highlights the potential of EV-based biomarkers in TBI, emphasizing their stability and tissue-specific signatures. Standardized protocols for EV isolation and characterization are needed for consistency across studies. While diagnostic applications have been explored, more research is required on the prognostic value of EV biomarkers, particularly for neurological outcomes, with future studies incorporating performance metrics to assess their clinical relevance.
参考来源
- Romero-García N, Ruiz-Pacheco A, Huete-Acevedo J, et al. Extracellular vesicles as a biomarkers in traumatic brain injury: a systematic review of animal and clinical studies. Crit Care. 2025. PMID: 40707934. doi:10.1186/s13054-025-05477-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。